GB 3226
Alternative Names: BRM-1420; GB-3226Latest Information Update: 17 Jul 2026
At a glance
- Originator Rockefeller University
- Developer Damora Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Transcription factor inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 06 Jul 2026 Galecto Biotech withdrew phase I study in Acute Myeloid Leukemia (Second-line therapy or greater, Monotherapy, Combination therapy) before enrollment due to business priority changes (NCT07084584)
- 10 Mar 2026 Galecto Inc is now called Damora Therapeutics
- 06 Dec 2025 Pharmacodynamics, adverse events and pharmacokinetics data from a Preclinical trials in Acute myeloid leukaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-2025)